Tocilizumab may be treatment option for thyroid eye disease

In a retrospective analysis of patients with active thyroid eye disease (TED) resistant to intravenous corticosteroids, intravenous tocilizumab was found to be a viable treatment option.

Of the 11 patients treated with a median of 5±3.2 doses, 20 eyes achieved inactivation of TED at week 16. Proptosis and diplopia response was achieved in 6 out of 8 patients and 3 out of 8 patients, respectively.

Overall, 9 patients demonstrated clinically significant improvement with the Graves’ orbitopathy Quality of Life (GO-QOL) questionnaire.

No serious adverse effects were reported during treatment, although 1 patient required decompressive surgery 15 months after treatment with tocilizumab.

Reference
Pampín-Sánchez R, Martínez-Mugica-Barbosa C, Fonseca-Aizpuru EM, et al. Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease. Med Clin (Barc). 2022;S0025-7753(22)00311-6. English, Spanish. doi: 10.1016/j.medcli.2022.05.007. Epub ahead of print. PMID: 36088128.